Early clinical evaluation of AcrySof ReSTOR multifocal intraocular lens for treatment of cataract

To evaluate the efficacy, safety and early visual quality of the AcrySof ReSTOR multifocal intraocular lens (IOL) following cataract surgery.

Eye Center of Shandong University of Traditional Chinese Medicine, Jinan Shierming Eye Hospital, Jinan, Shandong, China.

After small-incision phacoemulsification, AcrySof ReSTOR IOLs were implanted in 20 subjects (40 eyes, ReSTOR group). Monofocal IOLs were implanted in 18 subjects (36 eyes, control group). Three to six months following bilateral implantation, visual acuity, depth of focus, corneal astigmatism, contrast sensitivity, glare sensitivity, visual field and spherical aberration were compared between the groups. A subjective outcome questionnaire was also completed by the subjects.

Uncorrected near visual acuity 0.5 or better was achieved by 92.5% of the ReSTOR eyes. In the monofocal eyes, only 33.3% of the eyes achieved uncorrected near visual acuity of 0.5 or better. There was no statistical difference between corrected near, distance visual acuity, and uncorrected distance visual acuity in the 2 groups (p > 0.05). In patients with visual acuity 0.5 or better, the depth of focus was 4.87 +/- 1.09 and 2.08 +/- 0.69 dpt in the ReSTOR and control groups, respectively. The contrast sensitivity, glare sensitivity and visual field of both groups were similar (p > 0.05). The spherical aberration of the 2 groups was similar (t = -0.37, p = 0.71). Visual disturbances were minimal with only 1 patient in each group complaining of glare at night.

The AcrySof ReSTOR multifocal IOL is a safe and effective treatment for cataracts.